These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding. Shi J, Anderson D, Lynch BA, Castaigne JG, Foerch P, Lebon F. Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812 [Abstract] [Full Text] [Related]
25. Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. Stahl SM. J Clin Psychiatry; 2004 Sep; 65(9):1162-3. PubMed ID: 15367040 [Abstract] [Full Text] [Related]
26. Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy. Brochot A, Zamacona M, Stockis A. Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):256-62. PubMed ID: 20102365 [Abstract] [Full Text] [Related]
27. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Lynch JM, Tate SK, Kinirons P, Weale ME, Cavalleri GL, Depondt C, Murphy K, O'Rourke D, Doherty CP, Shianna KV, Wood NW, Sander JW, Delanty N, Goldstein DB, Sisodiya SM. Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120 [Abstract] [Full Text] [Related]
28. Exploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesis. Lee J, Daniels V, Sands ZA, Lebon F, Shi J, Biggin PC. PLoS One; 2015 Jan; 10(2):e0116589. PubMed ID: 25692762 [Abstract] [Full Text] [Related]
29. Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats. Ge YX, Lin YY, Bi QQ, Chen YJ. Curr Neurovasc Res; 2020 Jan; 17(4):354-360. PubMed ID: 32407277 [Abstract] [Full Text] [Related]
30. Brivaracetam: a novel antiepileptic drug for focal-onset seizures. Stephen LJ, Brodie MJ. Ther Adv Neurol Disord; 2018 Jan; 11():1756285617742081. PubMed ID: 29399049 [Abstract] [Full Text] [Related]
31. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation. Wang D, Zhou Q, Ren L, Lin Y, Gao L, Du J, Wang Y. Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049 [Abstract] [Full Text] [Related]
36. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany. Steinig I, von Podewils F, Möddel G, Bauer S, Klein KM, Paule E, Reif PS, Willems LM, Zöllner JP, Kunz R, Runge U, Kurlemann G, Schubert-Bast S, Rosenow F, Strzelczyk A. Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518 [Abstract] [Full Text] [Related]
37. Visualization of SV2A conformations in situ by the use of Protein Tomography. Lynch BA, Matagne A, Brännström A, von Euler A, Jansson M, Hauzenberger E, Söderhäll JA. Biochem Biophys Res Commun; 2008 Oct 31; 375(4):491-5. PubMed ID: 18692481 [Abstract] [Full Text] [Related]
38. Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. Zona C, Pieri M, Carunchio I, Curcio L, Klitgaard H, Margineanu DG. Epilepsy Res; 2010 Jan 31; 88(1):46-54. PubMed ID: 19914041 [Abstract] [Full Text] [Related]